Risk-share pays off for Lilly as it takes back migraine antibody
This article was originally published in Scrip
Eli Lilly is acquiring all rights to a therapeutic migraine antibody that it discovered and then licensed to new company Arteaus Therapeutics for development in 2011.
You may also be interested in...
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.